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CASPASE-12 (CASP12) has a down-regulatory function during infection, and thus may protect 
against inflammatory disease.  We investigated the distribution of CASP12 alleles (#rs497116) 
in African-Americans (AA) with rheumatoid arthritis (RA).  CASP12 alleles were genotyped in 
953 RA patients and 342 controls.  Statistical analyses comparing genotype groups were 
performed using Kruskal-Wallis non-parametric ANOVA with Mann-Whitney U tests and chi-
square tests.  There was no significant difference in the overall distribution of CASP12 
genotypes within AA with RA, but CASP12 homozygous patients had lower baseline joint 
narrowing and total disease scores.  CASP12 homozygosity appears to be a subtle protective 





 The pathogenesis of rheumatoid arthritis (RA) is multi-factorial, with contributions from 
environmental factors and a strong genetic component.  To date, at least 46 genes are known 
risk factors for the development of RA (Eyre et al. 2012; Killock 2013).  We sought to determine 
the role of CASPASE-12 (CASP12), a well-studied gene whose murine homologue is involved 
in cellular stress transmitted via the endoplasmic reticulum (Rao et al. 2001), in the 
development of RA.  
 Most humans lack a functional CASP12 gene.  A pseudogene (CASP12p1) resulting 
from a premature termination mutation is found in all Caucasians and East Asians examined, 
and in 80% of people of African lineage (Saleh et al. 2004).  In approximately 20% of persons of 
recent African descent, the pseudogene is rescued by a single nucleotide polymorphism 
(#rs497116; A->G) that converts the premature stop codon into a functional one encoding Arg.  
This functional allele is a risk factor for sepsis in persons of African descent due to its ability to 
down-regulate inflammatory cytokines such as interleukin (IL)-1β, in responses to pro-
inflammatory mediators such as bacterial lipopolysaccharide (Saleh et al. 2004).  In individuals 
of African descent with severe sepsis, the mortality rate was 54% in individuals with the 
CASP12 allele, compared with 17% in individuals with only the CASP12p1 allele. Knockout 
mice lacking CASP12 are also less susceptible to sepsis and death than wild-type (Saleh et al. 
2006).  This contrasts with susceptibility to fungal septicemia, which does not correlate with 
CASP12 genotype (Rosentul et al. 2011). 
 A corollary to the observation that CASP12 is a risk factor for sepsis would be that 
CASP12 is protective against some inflammatory autoimmune diseases.  We decided to test 
this hypothesis with the Consortium for Longitudinal Evaluation of African-Americans with Early 
Rheumatoid Arthritis (CLEAR) and the Veterans Administration Rheumatoid Arthritis (VARA) 
Registry of African-Americans with RA.  CLEAR and VARA are multicenter chronic disease 
registry programs enrolling self-defined African Americans with RA as defined by the revised 
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American College of Rheumatology (ACR) classification criteria. Both have been described 




Single nucleotide polymorphism genotyping of CASP12 (#rs497116; A->G) was performed in a 
single tube assay (Waterfall and Cobb 2001) by allele-specific polymerase chain reaction (PCR) 
using primers containing a mismatch introduced at the second base from the 3’ end to improve 
allele specificity (Pettersson et al. 2003).    PCR products were analyzed on 1% agarose gels.  
To verify results, 200 bp from the polymorphic region of CASP12 exon 2 was amplified and 
subjected to DNA sequencing using a high-fidelity DNA polymerase.  Sequence analysis was 
sensitive enough to discriminate between homozygous and heterozygous individuals.   
2.2 Statistical analysis 
 The relationship of discrete variables to genotype was assessed with Fisher's Exact test.  
The relationship of continuous variables to genotype was first assessed with a Kruskal-Wallis 
non-parametric ANOVA.  If the ANOVA was significant (p<0.05), a Mann Whitney U test was 
used to determine which groups were different.  
3. Results 
 To determine if CASP12 would have an effect upon the pathologic manifestations of RA 
due to its anti-inflammatory functions, we genotyped the CASP12 SNP rs497116 in 953 patients 
and 342 controls.  Clinical and demographic data on our subjects are shown in Table 1.  The 
data in Table 2 show that frequencies of CASP12 alleles in both patients and controls were 
similar to each other, and to normal controls reported by others (Saleh et al. 2004).  
Furthermore, genotype did not affect seropositivity of rheumatoid factor (χ2=4.1, p=0.128) or 
anti-citrullinated peptide antibodies (χ2=1, p=0.618).  As expected, while nearly 20% of the 
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controls were positive for RF, and only 3% were so for anti-CCP, there was no connection to 
CASP12 genotype in either group (Supplemental Table 1).  
 We then compared the distribution of CASP12 alleles in 697 CLEAR patients for whom 
we had additional data on the ACR diagnostic criteria for RA.  We also assessed CASP12 
genotype in 742 CLEAR patients for whom we had data on the presence or absence of 
subcutaneous or rheumatoid nodules.    No significant differences were found for the clinical 
parameters of baseline joint tenderness or swelling scores, or elevations in the inflammatory 
markers C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR).  The results of the 
analysis can be seen in Supplemental Table 2. 
 Despite the lack of correlation between CASP12 genotype and joint swelling or pain, 
patients with CASP12 had decreased scores for joint pathologies as discerned upon 
radiographic changes.  Figure 1 shows the data given as a strict genotypic distribution for all 
patients.  While joint erosion scores were barely significant between the homozygous groups, 
and were not significant between the CASP12p1 homozygous and heterozygous groups (p = 
0.15), baseline joint narrowing and overall disease scores were greater in those patients who 
were homozygous for the CASP12p1 pseudogene than those who were CASP12 homozygous.  
In addition, heterozygotes had significantly different lower joint narrowing and total scores than 
did the CASP12p1 homozygotes, but to a lesser extent than the CASP12 homozygotes. 
 For joint narrowing or overall scores (defined as joint erosion + narrowing scores) >0, 
patients homozygous for CASP12p1 had higher mean and maximum scores (p = 0.008).  While 
only three CASP12 homozygous patients had pathologic scores (i.e., a score >0), it was striking 
that the maximum value in this group was 28, compared to 181 and 341 for heterozygotes and 
CASP12p1 homozygotes, respectively (p = 0.002).  There were no significant differences 
between CASP12p1 homozygotes and heterozygotes in these three categories.  Similar data 
was noted for joint narrowing, with maximum scores of 11 vs 117 vs 166 (p = 0.008).  In 
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addition, radiologic pathology scores also appeared to be lesser in heterozygotes as compared 
than CASP12p1 homozygotes, although not reaching statistical significance.    
4. Discussion 
 We have shown that while possession of the intact CASP12 has no overall effect upon 
the development of RA in AA, there is a subtle protective effect against the erosive pathologies 
of RA.  The findings thus potentially point to pathways involved in the severity of joint damage.   
While the number of normal controls in our study are approximately one third the patient 
sample, the allele frequencies for controls and patients are nearly identical to those of Saleh et 
al (2004) who used 623 normal subjects. While the small numbers of CASP12 homozygous 
patients we identified are a limitation, CASP12/p1 heterozygotes also had significantly lower 
joint narrowing and overall scores, which complement the genotypic effect upon inflammatory 
cytokine production as observed by Saleh and colleagues (Saleh et al. 2004). 
 The study used all available data so our power was restricted by the data available.  
While we did not have patient numbers to have power to detect an odds ratio of 1.2, (which 
would require a very large sample number), there were 579 individuals with the CASPp1 
homozygous genotype and 163 individuals with at least one CASP12 allele.  This provided 81% 
power to detect an odds ratio of 1.69 (if the proportions being compared are 0.300 and 0.420).  
While it would be desirable to be able to detect a smaller odds ratio, there is sufficient power to 
indicate whether there is an association worthy of future study, as there are very few confirmed 
genetic markers of RA severity and this polymorphism could explain inter-ethnic differences in 
radiological damage. 
   It is unknown how CASP12 exerts these protective effects.  CASP12 is proposed to bind 
to the inflammasome and inhibit CASP1 activity, preventing the maturation and release of IL-1β 
(Saleh et al. 2006; Saleh et al. 2004).  Yet the published data is contradictory as to whether 
CASP12 actually reduces IL-1β in humans.  CASP12 genotype does not influence the 
susceptibility to Candida sepsis in Africans, nor does it have any effect on serum cytokine 
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concentrations in septic candidiasis patients (Rosentul et al. 2011) or in responses to Yersinia 
pestis (Ferwerda et al. 2009).  CASP12’s effects upon TNF production, which is pathogenic in 
RA (Boissier et al. 2012; Choy 2012), is also contradictory (Ferwerda et al. 2009; Plantinga et 
al. 2010; Yeretssian et al. 2009).  These differences may be due to sample size, the populations 
tested, or the assay systems used.  If CASP12 is indeed down-regulatory, it may fail to reduce 
serum concentrations of IL-1β and other pro-inflammatory cytokines below disease-inducing 
levels, but does so in the synovium or synovial fluid.  It is also possible that CASP12 acts via an 
inflammasome-independent pathway, as CASP1 is upregulated in RA patients (Mathews et al. 
2013), and the inflammasome does not appear to play an overt role in joint pathology (Kolly et 
al. 2010; So et al. 2013).  Murine CASP12 interferes with NOD signaling by competitively 
competing for binding on RIP2 with TRAF6 (LeBlanc et al. 2008), and both NOD1 and TRAF6 
contribute to RA pathogenesis (Plantinga et al. 2013; Zhu et al. 2012). 
 Examination of levels of pro-inflammatory cytokines in serum and synovial fluid from AA 
with RA may help discern whether CASP12 has systemic effects or within joint-invasive 
mononuclear cells.  In addition, as data on CASP12 expression in normal or diseased human 
tissues is also lacking, further study of CASP12 expression may yield clues to this protein’s 
molecular mode of action.   
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Fig. 1 CASP12 genotype affects radiologic measures of RA pathogenesis in AA.  Abbreviations 
are as per Table 2.  A, Joint erosion score at baseline; B, Joint space narrowing score at 
baseline; C, Overall score at baseline (Erosion + joint space narrowing).  Units for joint erosions 
and narrowing as determined by radiographic data have been described in detail in (Bridges et 
al. 2010); briefly, radiographs were categorized as not having damage (total score = 0) or 
having damage (total score > 0). Analyses on data were performed using non-parametric 2-
tailed t tests with Mann-Whitney corrections.   
